Latest press releases
-
- Feb 9, 2006
- ASTRAZENECA ANNOUNCES FIRST REGULATORY APPROVAL FOR NEW HFA pMDI FOR PULMICORT® February 9, 2006, Lund, Sweden. AstraZeneca announced today the approval in Finland, as the first approval in the first European market, of a new pressurised metered-dose inhaler (pMDI) formulation of the inhaled corticosteroid Pulmicort® (budesonide) for the treatment of asthma in adults and children.
-
- Dec 15, 2005
- LARGEST EVER ASTHMA TRIAL HIGHLIGHTS SAFETY OF PULMICORT® TREATMENT DURING PREGNANCY Lund, Sweden, December 15, 2005: Five year results from the START trial (inhaled Steroid Treatment As Regular Therapy in early asthma), published today in Annals of Allergy, Asthma & Immunology, reveal that treating mild, persistent asthma during pregnancy with Pulmicort® (budesonide) results in similar number of healthy children delivered in comparison to treatment with placebo[1].
-
- Sep 19, 2005
- ANALYSIS SHOWS FOR THE FIRST TIME THAT INHALED CORTICOSTEROIDS PROTECT AGAINST CARDIO-ISCHAEMIC EVENTS IN COPD 19th September 2005, European Respiratory Society Congress, Copenhagen: For the first time, the inhaled corticosteroid (ICS) budesonide - a common treatment for Chronic Obstructive Pulmonary Disease (COPD) - has been shown to reduce cardio-ischemic events in patients with mild to moderate COPD, according to a post-hoc a analysis of the EUROSCOP study, presented at the European Respiratory Society (ERS) Congress in Copenhagen today.[1]
-
- Jun 28, 2005
- ASTRAZENECA SUBMITS REGULATORY APPLICATION FOR NEW HFA pMDI FOR PULMICORT® 28 June, 2005. Lund, Sweden. AstraZeneca announced today the filing in the first European markets, of a new pressurised metered-dose inhaler (pMDI) formulation of the inhaled corticosteroid Pulmicort® (budesonide) for the treatment of asthma in adults and children. The currently available chlorofluorocarbon (CFC) pMDI formulation has been on the market since December 1981 and, in accordance with the Montreal Protocol, will be replaced by a non-ozone depleting device based on hydrofluoroalkanes (HFA).
-
- May 22, 2005
- INHALED BUDESONIDE MAY SLOW DOWN DISEASE PROGRESSION IN SMOKERS WITH COPD 22 May, 2005. Lund, Sweden: New research among smokers with the lung condition Chronic Obstructive Pulmonary Disease (COPD), presented today at the American Thoracic Society Congress (ATS), reveals that budesonide (Pulmicort®), an inhaled corticosteroid (ICS) with well-proven efficacy and safety in asthma and a common treatment for COPD, may have a protective effect on the development of emphysema.
-
- Jan 24, 2005
- NEW LONG-TERM TOLERABILITY DATA FOR PULMICORT® STRENGTHENS EXISTING EVIDENCE FOR EARLY INTERVENTION IN ASTHMA Lund, Sweden, November 24, 2004: New results from the START study1 are published today in the Annals of Allergy, Asthma and Immunology, revealing three-year safety outcome data for Pulmicort (budesonide). These data further reinforce previous findingsthat Pulmicort in low doses is well tolerated in long term treatment of asthma in both adults and children.
Not signed in
PubMed
Interactive disease tutorials
Interactive patient sites
Notice
This international site is intended for health-care professionals.
Patients & carers should visit New To Asthma.com.
Patients & carers should visit New To Asthma.com.
